Clinical Trials authorized in Uganda since 2016 – Updated on 2nd July 2024

S/NCTA #Title Date of initial AuthorizationPrincipal InvestigatorInstitutionSponsorStatus Duration of the trial
10001Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-center, parallel-group, two arm randomized placebo controlled superiority trial.04/04/2016Assoc Prof. Robert Opoka Opoka Department of Pediatrics and Child Health, MUCHS Liverpool School of Tropical Medicine (LSTM)Closed Out
20002Doxycycline for the treatment of nodding syndrome: A phase II, randomized placebo controlled trial.05/04/2016Assoc Prof. Richard IdroDepartment of Pediatrics and Child Health, MUCHSOngoing
30003Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability, and Anti-Retroviral Activity of GSK 1349572 (Dolutegravir), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents. (IMPAACT P1093)19/05/2016Dr. Maxensia OworMakerere University – John Hopkins University (MUJHU) Care Ltd. United States National Institute of HealthOngoing
40004Prevention of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 3)09/08/2016Prof. Moses KamyaMU-UCSF Closed Out
50005A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS -9883/ Emtricitabine/Tenofovir Alafenamide (GS - 9883/F/TAF) from Elvitegravir /Cobicistat /Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF), or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumerate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women.11/05/2016Dr. Cissy Kityo Mutuluza Joint Clinical Research Centre Gilead SciencesOngoing
60006A randomized trial of dolutegravir (DTG)-based antiretroviral therapy vs standard of care (SOC) in children with HIV infection starting first line or switching to second line ART. (ODYSSEY PENTA 20)15/07/2016Dr. Cissy Kityo MutuluzaJoint Clinical Research CentreClosed out
70007Pharmacokinetics of efavirenz 400 mg once daily during pregnancy in HIV -1 infected women.07/07/2016Prof.Mohammed LamordeInfectious Diseases Institute Closed out
80008Investigation of rheumatic AF Treatment Using Vitamin K antagonists, rivaroxaban or aspirin Studies. (INVICTUS) 12/12/2016Dr. Emmy OkelloUganda Heart InstitutePopulation Health Research InstituteClosed-out
90009A Multi-center, Phase 3B Open-label Follow-up trial to assess the continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women. (MTN 025)05/09/2016Dr. Brenda Gati Mirembe Makerere University – John Hopkins University (MUJHU) R Care Ltd. Division of AIDS(DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIH)Closed out
100010A Multi-country, prospective, clinical safety study of subjects exposed to the candidate Ebola vaccines Ad26.ZEBOV and/or MVA –BN-Filo.02/09/2016Prof. Pontiano KaleebuThe Medical Research Council/Uganda Virus Research Institute (MRC/UVRI)Janssen VaccineOngoing
110011A Pharmacokinetic Evaluation of Increased Dose Levonorgestrel Implant and Efavirenz-Based Antiretroviral Therapy In HIV-Infected Women.10/03/2017Dr. Mohammed Lamorde Infectious Diseases Institute Ongoing
120012A multicenter, open label, randomized, multiple dose, two period crossover, bioequivalence study of Liposomal Amphotericin B injection (Cipla Ltd., India) and AmBisome® Liposome for injection (Gilead life sciences, USA ) in adult patients with fungal infections. 01/11/2016Dr. Henry MugerwaJoint Clinical Research CentreClosed out
130013A Follow-Up Open Label Trial to Assess The Continued Safety of and Adherence to the Dapivirine (25mg) Vaginal Ring-004 in Healthy HIV-Negative Women (Phase IIIb) 10/10/2016Dr. Sylvia KusemererwaThe Medical Research Council/Uganda Virus Research Institute (MRC/UVRI)Closed-out
140014Strategy for Maintenance of HIV Suppression with Elvitegravir + Darunavir +Ritonavir in Children. (SMILE PROTOCOL)06/02/2017Dr. Victor Musiime Joint Clinical Research CentrePENTA FoundationAmended to CTA0065
150015Defining the Molecular profile of Breast Cancer in Uganda and its Clinical Implications02/03/2017Dr. Jackson OremUganda Cancer InstituteGSKClosed Out36 Months
160016Optimizing Hydroxyurea Therapy in Children with Sickle Cell Anemia in Malaria Endemic Areas : The NOHARM Maximum Tolerated Dose (MTD) Extension Study 28/03/2017Dr. Robert Opika Opoka Global Health Uganda / Pediatric Department, Mulago Hospital Doris Duke Charitable FoundationOngoing
170017The effect of modified F-75 on diarrhea in the treatment of children with severe acute malnutrition.31/01/2017Dr. Elizabeth Kiboneka Mwana Mugimu Nutrition Unit, Mulago HospitalUniversity of CopenhagenTerminated
180018A Phase 2/3 , Open Label Study of the Pharmacokinetics , Safety, and Antiviral Activity of the GS-9883/ Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) in HIV-1 infected Virologically Suppressed Adolescents and Children17/03/2017Dr. Eva NatukundaJoint Clinical Research CentreGilead SciencesOngoing
190019Anti-retroviral therapy for acute HIV infection15/02/2018Dr. Francis KiweewaMakerere University Walter Reed Project.Henry M Jackson Foundation, United States Military HIV Research ProgramClosed out24 Months
200021An open label phase I clinical trial to evaluate the effect of late boost on HIV-uninfected vaccines from EV06 trial10/03/2017Prof. Pontiano Kaleebu The Medical Research Council/Uganda Virus Research Institute (MRC/UVRI)Henry M Jackson Foundation, PEPFARClosed out
210022Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans (CREOLE) 31/05/2017Dr. Mondo Charles Kiiza St. Francis Hospital NsambyaUniversity of AbujaTBC36 Months
220023Phase 1 Safety and Pharmacokinetic Study of Maraviroc in HIV-1- Exposed Infants at Risk of Acquiring HIV-I Infection14/06/2017Dr. Jesca Nakibuuka MU-JHU Care Ltd.Division of AIDS (DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIH)Withdrawn28 Months
230024Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial26/04/2017Dr. Cissy Kityo MutuluuzaJoint Clinical Research CentreCenters for Disease Control and Prevention (CDC) in collaboration with AIDS Clinical Trials Group (ACTG) Closed-out
240025An international multi-center controlled clinical trial to evaluate 1200mg and 1800mg rifampicin daily in the reduction of treatment duration for pulmonary tuberculosis from 6 months to 4 months (Rifashort) 14/06/2017Dr. Daniel Atwine Epicentre - Mbarara Research Base St George University of LondonOngoing36 Months
250026Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis among Women at High Risk for HIV infection in Kampala, Uganda 29/03/2017Prof. Janet Seeley The Medical Research Council/Uganda Virus Research Institute (MRC/UVRI)London School of Hygiene and Tropical MedicineClosed-out
260027The evaluation of a standard treatment regimen of anti-tuberculosis drugs for patients with MDR-TB (STREAM) 23/05/2017Dr. Bruce Kirenga Makerere University – Lung Institute (MLI)The International Union Against the TB and Lung Disease (IUATLD)Closed-out60 Months
270028Assessing the tolerability and safety of single low dose Primaquine in African Children with Acute Uncomplicated Falciparum Malaria and Glucose-6-Phoasphate Dehydrogenase Deficiency.22/06/2017Dr. Peter Olupot-Olupot Mbale Clinical Research Institute (MCRI)Mahidol Oxford Research Unit-University of OxfordOngoing60 Months
280029First line Antimicrobials in Children with complicated Severe Acute Malnutrition. (FLACSAM)22/06/2017Dr. Peter Olupot-Olupot Mbale Clinical Research Institute (MCRI)Oxford UniversityOngoing36 Months
290030IMPAACT 2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir Containing versus Efavirenz Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants. 29/09/2017Dr. Deo WabwireMU-JHU Care Ltd.Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID)Closed-out48 Months
300031Randomized clinical trial evaluating sertraline plus fluconazole verses fluconazole alone for pre-emptive treatment of asymptomatic cryptococcal antigenemia in HIV-Infected persons living with AIDS.11/08/2017Dr. David MeyaInfectious Diseases InstituteClosed-out48 Months
310032IMPAACT 2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir –Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1 Infected Pregnant Women and their Infants 20/10/2017Dr. Violet KorutaroBaylor College of Medicine Children’s Foundation UgandaDivision of AIDS(DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIH)Ongoing48 Months
320033HPTN084: A Phase 3 Double Blind Safety and Efficacy Study of Long Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV- Uninfected Women.13/10/2017Dr. Clemensia NakabiitoMU-JHU Care Ltd.Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH),Ongoing60 Months
330034A Randomized, blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines (YEFE)04/10/2017Dr. Maria Loiuse NamulwanaEpicentre - Mbarara Research Base Rebecca Grais, Director Research EpicenterClosed out 48 Months
340035Randomized Trial to Prevent Vascular Events in HIV-REPRIEVE. Protocol No: A533227/09/2017Prof. Cissy Kityo MutuluuzaJoint Clinical Research CentreDivision of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH),Closed Out 96 Months
350036Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses11/12/2017Dr Cissy KityoJoint Clinical Research CentreNational Institute of Allergy and Infectious Diseases (NIAID)Closed-out18 Months
360037A Phase II interventional multi-center randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersible Formulation in the combination given once daily for 1,2 and 3 days to adults and children with uncomplicated Plasmodium Falciparum Malaria. 09/03/2018Dr. Adoke YekaInfectious Diseases Research CollaborationNovartis Pharma AGClosed Out36 Months
370038A Phase II interventional multi-center randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersible Formulation in the combination given once daily for 1,2,and 3 days to adults and children with uncomplicated Plasmodium Falciparum Malaria10/01/2018Dr. Sylvia KusemererwaMRC/UVRINovartis PharmaceuticalsClosed-out 36 Months
380039Optimizing iron status while minimizing morbidity in HIV-Infected Ugandan Children 03/01/2018Dr. Victor MusiimeJoint Clinical Research CentreUniversity of Minnesota Msonic Cross-Departmental Grants for Children’s Health ResearchOngoing36 Months
390040An open Label Phase III Randomized Controlled Multicenter Non inferiority Trial to compare Efficacy and Safety of Miltefosine and Paramomycin with Sodium Stigbogluconate and Paramomycin combination for the treatment of Primary Visceral Leishmaniasis (VL) patients in East Africa. 22/01/2018Prof. Joseph OloboDepartment of Immunology and Molecular Biology, Makerere UniversityDrugs For Neglected Diseases Initiative (DNDi)Closed out
400041Testing the ability of a microbiome-focused intervention to reduce HIV susceptibility in Ugandan men. Protocol No: TmHIV-01 17/10/2017Dr. Bernard S. BagayaUVRI-IAVI HIV Vaccine ProgramCanadia Institute of Health Research (CIHR)Ongoing31 Months
410042Dolutegravir in Pregnant HIV Mother and their Neonates (DOLPHIN-2)12/12/2017Dr. Mohammed LamordeInfectious Diseases InstituteUniversity of LiverpoolClosed Out
420043A Pilot Study of Nelfinavir for the Treatment of Kaposi’s Sarcoma (AmC 098).16/10/2018Dr. Jackson OremUganda Cancer InstituteAIDS Malignancy Consortium (AMC)Ongoing36 Months
430044A phase 2a Crossover Trial to Evaluate the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population.09/07/2018Dr. Carolyne Agwau AkelloMU-JHU Research CollaborationDivision of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Health (NIH)Ongoing36 Months
440045Steady-state pharmacokinetics of Efavirenz (Stocrin) 400 mg once daily in the presence of rifampicin and isoniazid (Rifinah or the local generics). Protocol SSAT06203/01/2018Dr. Mohammed LamordeInfectious Diseases InstituteSt Stephens' AIDS Trust, LondonClosed out24 Months
450046HIV Self-testing to empower Prevention Choices in Sex workers. 03/01/2018Dr. Andrew MujugiraInfectious Diseases InstituteForgaty International CenterOngoing9 Months
460047A Randomized, Double-Blind, Efficacy and Safety Study of Azilsartan Medoxomil Treatment and Withdrawal, followed by Open-Label Extension, in Children 6 to Less Than 18 Years of Age with Hypertension .N/ADr. Henry MugerwaJoint Clinical Research Center Rejected58 Months
470048Simplified Isoniazid Preventive Therapy (SPIRIT) Strategy to reduce TB burden 08/11/2018Prof. Moses KamyaInfectious Diseases Research CollaborationNational Institute of Allergy and Infectious Diseases (NIAID)Ongoing 36 Months
480049A phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women. (HPTN 084)04/04/2018Dr. Patricia Nahirya NtegeBaylor College of Medicine Children’s FoundationDivision of AIDS(DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), US National Institute of Health (NIH)Ongoing54 Months
490050A Phase 2, multicenter, randomized open-label, dose escalation study to determine safety of single (QD) and multiple (3 QD) doses of KAE609, given to adults with uncomplicated Plasmodium falciparum malaria06/03/2018Dr. Henry MugerwaJoint Clinical Research CentreNovartis Pharma AGClosed out 18 Months
500051A Phase 2, multicenter, randomized open-label, dose escalation study to determine safety of single (QD) and multiple (3 QD) doses of KAE609, given to adults with uncomplicated Plasmodium falciparum malaria28/02/2018Dr. Stephen AsiimweKabwohe Clinical Research CentreNovartis Pharma AGClosed Out18 Months
510052A Phase 2, Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)ide Reverse Transcriptase Inhibitor-Containing Regimen with Nucloes(t)ide Transcriptase Inhibitor Resistant Virus, Followed by Continued Treatment with a GS-9131+Bictegravir+Darunavir+Ritonavir Regimen. Protocol Number: GS-US-442-414806/02/2018Dr. Cissy Kityo MutuluuzaJoint Clinical Research CentreGilead SciencesOngoing30 Months
520053HIV Self-Testing and PrEP to Increase Testing and Prevention Uptake among Male Partners and improve postpartum ART Use in PMTCT B+ Programs in Uganda 03/01/2018Professor Elly KatabiraInfectious Diseases InstituteUS National Institute of Mental HealthClosed out
530054Impact of Concurrent Initiation of DMPA Contraception and Tenofovir PrEP on Bone Loss in Young Women. 17/04/2018Professor Elly KatabiraInfectious Diseases InstituteUniversity of Washington,Ongoing42 Months
540055A Pharmacokinetic Evaluation of Etonogestrel Implant in HIV-Infected Women on Darunavir Versus Rilpivirine-Based Antiretroviral Therapy. (DRIVE-1) 26/06/2018Prof. Mohammed LamordeInfectious Diseases InstituteInfectious Diseases InstituteClosed Out 24 Months
550056A Pharmacokinetic Evaluation of Levonorgestrel Implant in HIV-Infected Women on Darunavir versus Rilpivirine-based Antiretroviral Therapy. (DRIVE-2) 27/06/2018Prof. Mohammed LamordeInfectious Diseases InstituteInfectious Diseases InstituteClosed Out24 Months
560057A Phase 2, multicenter, randomized open-label, dose escalation study to determine safety of single (QD) and multiple (3 QD) doses of KAE609, given to adults with uncomplicated Plasmodium falciparum malaria.01/03/2018Dr. Adoke YekaInfectious Diseases Research CollaborationNovartisClosed Out 18 Months
570058A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV Uninfected Women04/04/2018Dr. Juliet MpendoUganda Virus Research Institute-International AIDS Vaccine InitiativeDivision of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH)Ongoing56 Months
580060Integrated PrEP and ART delivered in Ugandan public health clinics to improve HIV and ART outcomes for HIV serodiscordant couples. 21/06/2018Prof. Elly KatabiraInfectious Diseases InstituteUniversity of WashingtonOngoing
590061High-Dose Intravenous Rifampicin to Improve Survival of Tuberculosis Meningitis: A phase II open-label randomized controlled trial (RifT Study).18/06/2018Dr. David B. MeyaInfectious Diseases InstituteInfectious Diseases InstituteClosed Out36 Months
600062IMPAACT 2009: Pharmacokinetics, Feasibility, Acceptability and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants.22/06/2018Dr. Clemensia NakabiitoMUJHU Research CollaborationNational Institute of Allergy and Infectious Diseases (NIAID)Closed Out 9 Months
610063EMaBS TB Vaccine Study: Open label, dose escalation and age de-escalation for ChAdox1 85A in Ugandan adults and adolescents, followed by a Phase IIa randomized, open-label trial among adolescents comparing ChAdOx1 85A prime followed by MVA85A boost versus BCG re-vaccination. 20/07/2018Prof. Alison ElliotMRC/UVRI and LSHTM Uganda Research UnitUniversity of Oxford Clinical Trials and Research Governance Joint Research OfficeOngoing30 Months
620064High Dose AMBISOME on a fluconazole backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Phase 3 Randomized Non- Inferiority Trial (AMBITION-CM). 22/06/2018Dr. David MeyaInfectious Diseases InstituteLondon School of Hygiene and Tropical Medicine (LSHTM)Closed-out48 Months
630065A Phase 2/3 Multi-center, Open-label, Randomized study evaluating the Safety and Anti-viral effect of once daily integrase inhibitor administered with Darunavir/ritonavir (DRV/r) compared to current Standard of Care (SOC) antiretroviral therapy in HIV-1 infected, virologically suppressed Pediatric participants. 22/06/2018Dr. Victor MusiimeJoint Clinical Research CentrePENTA FoundationClosed Out72 Months
640066Children with HIV in Africa - Pharmacokinetics and Acceptability of Simple Second-line Anti-Retroviral Regimens.29/07/2018Dr. Victor MusiimeJoint Clinical Research CentreUniversity College of LondonClosed out60 Months
650067Efficacy and Safety of Artemether-Lumefantrine, Artesunate-Amodiaquine and Dihydroartemisinin-Piperaquine for The Treatment of Uncomplicated Plasmodium Falciparum Malaria in Uganda.04/07/2018Dr. Adoke YekaInfectious Diseases Research CollaborationNational Malaria Consortium Program, MOH, WHO Country officeOngoing21 Months
660068“GwokO Adunu pa Lutino” (GOAL Trial) – Determining the Impact of Penicillin on Latent Rheumatic Heart Disease: A Randomized Controlled Trial20/08/2018Dr. Emmy OkelloUganda Heart InstituteChildren’s National Medical CentreClosed Out36 Months
670069Encochleated Oral Amphotericin for Cryptococcal Meningitis. (EnACT) 04/10/2018Dr. David B. MeyaInfectious Diseases InstituteMatinaas Biopharma Nanotechnologies, Inc USAClosed out 24 Months
680070A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of an Ebola Sudan Chimpanzee Adenovirus Vector Vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), in Healthy Adults.26/11/2018Dr. Betty MwesigwaMakerere University Walter Reed Project (MUWRP)National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH), Vaccine Research Centre (VRC) Bethesda, MarylandOngoing24 Months
690071Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS)23/08/2018Assoc Prof. Robert OpokaDepartment of Pediatrics and Child Health, MUCHSThrasher Research FundOngoing12 Months
700072An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSV?G-ZEBOV-GP. 21/09/2018Assoc Prof. Juliet Mwanga AmumpaireEpicenter Mbarara Research CenterMedicins Sans Frontieres (MSF)OngoingUndetermined
710073A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola vaccines Ad26.ZEBOV and/or MVA-BN-Filo, Phase 3.02/11/2018Dr. Hannah KibuukaMakerere University Walter Reed ProjectJanssen Vaccines and Prevention B.VClosed Out60 Months
720074A Randomized, Placebo-controlled Trial of HPV vaccination to reduce Cervical High-Grade Squamous Intraepithelial Lesions among HIV-infected Women Participating in an HPV Test-and-Treat Program. (CONVENANT)10/12/2018Dr. Jackson OremUganda Cancer InstituteNational Cancer Institute, Office of HIV and AIDS MalignancyTBC60 Months
730075Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old in Uganda.12/10/2018Dr. Irene LubegaInfectious Diseases InstituteCentre For Disease Control and PreventionOngoing36 Months
740076A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavarin-free HCV Therapy to HCV Infected Populations who are HCV Treatment Naïve with Evidence of Active HCV Infection. (The MINMON study)26/11/2018Dr. Cissy KityoJoint Clinical Research CentreNational Institute of Allergy and Infectious Diseases (NIAID)Closed Out30 Months
750077An Open-label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4 Month Treatment of Bedaquiline plus Pretomanid plus Moxifloxacin plus Pyrazinamide (BPaMZ) Compared to a 6 Month Treatment of HRZE/HR (Control) in Adult Participants with Drug- Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants with Drug-Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)04/12/2018Prof. Harriet Mayanja KizzaCase Western Reserve University Research Collaboration (CWRU)Global Alliance for TB Drug DevelopmentClosed Out36 Months
760078A Phase 2, Open-label, Multicenter, Single arm study to evaluate the Pharmacokinetics, Safety, Tolerability and Anti-Mycobacterial activity of TCM207 in combination with a Background regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for the treatment of children and adolescents 0 months to <18 years of age who have Confirmed or Probable Pulmonary MDR-TB Protocol TMC207-C211 12/09/2019Dr. Rebecca NantandaMUCHS, Makerere University Lung InstituteJanssen PharmaceuticalsOngoing60 Months
770079A Randomized, Double-Blind, Parallel-Group, Multicenter, Phase III Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Pediatric Patients with Sickle Cell Disease. (HESTIA3) 23/01/2019Assoc Prof. Victor MusiimeJoint Clinical Research CentreAstra Zeneca AB, SwedenTerminated24 Months
780080Pharmacokinetic and Pharmacodynamic Evaluation of Etonogesterol Dose Escalation with Efavirenz based Antiretroviral Therapy in HIV-infected Ugandan Women. (PK-20)07/01/2019Prof. Mohammed LamordeInfectious Diseases instituteUniversity of PittsburghOngoing 36 Months
790081Compassionate healthcare and frontline workers and ring vaccination project intended to evaluate safety of the Ebola vaccine in Uganda. Version 1 Expanded Access-Uganda26/11/2018Dr. Bernard OparMinistry of Health Uganda supported by the World Health OrganizationWorld Health OrganizationTerminated
800084IMPAACT 2009: Pharmacokinetics, Feasibility, Acceptability and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants.26/11/2018Dr. Nicolette Nabukeera BarungiBaylor College of Medicine Children’s FoundationNational Institute of Allergy and Infectious Diseases (NIAID)Ongoing36 Months
810086“Randomized trial to compare Magnesium Sulphate administration for preeclampsia and eclampsia: Springfusor versus standard approach18/01/2019Dr. Sam OnongeDepartment of Obstetrics and Gynecology, Makerere University College of Health SciencesMakerere University College of Health SciencesClosed Out24 Months
820087A Randomized, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease. (HESTIA3)30/01/2019Dr. Kibuuka AfiziInfectious Diseases Research CollaborationAstra ZenecaNot Initiated24 Months
830088Effect of preoperative bicarbonate on Maternal and Perinatal outcomes of obstructed labor; A Study Protocol for a Randomized Controlled Trial 23/01/2019Dr. Milton Musaba WambokoDepartment of Obstetrics and Gynecology, Makerere University College of Health SciencesSurvival Pluss Project NORA/NORHED ProgramClosed Out 12 Months
840089A Randomized, Four-arm Open-Label Phase IIb Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected patients on Efavirenz-or Dolutegravir based Antiretroviral Therapy. (SAEFRIF) 15/03/2019Dr. Christine SekaggyaInfectious Diseases Institute,Makerere University College of Health SciencesInfectious Diseases InstituteOngoing
850090A Phase I/II, Open-Label, Randomized Crossover Pharmacokinetic, Safety and Acceptability Study of the Abacavir/Lamivudine/Lopinavir/Ritonavir/ - 30/15/40/10mg (4-in-1) Fixed Dose Combination vs Lopinavir/Ritonavir - 40/10mg pellets plus Dual Abacavir/Lamivudine - 60/30mg Tablets in HIV Infected Children.20/01/2019Assoc Prof. Victor MusiimeJoint Clinical Research CentreDrugs for Neglected Diseases Initiative (DNDI) SwitzerlandEarly Termination by the Sponsor12 Months
860091Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia. (ACACIA)23/04/2019Assoc Prof. David MeyaInfectious Diseases InstituteInfectious Diseases InstituteOngoing60 Months
870092Optimizing benefits while reducing risks of iron in malaria-endemic areas: The OptiM 15/03/2019Dr. Ezekiel MupereDepartment of Pediatrics and Child healthUniversity of MinnesotaOngoing
880093Population Difference in Vaccine Response: The Role, Reversibility and Mediators of Immunomodulation by Chronic Infections in the Tropics (POPVAC).” – Protocol A: The Effect of Intensive Treatment for Schistosomiasis on Response to Vaccines among Island Adolescents.28/05/2019Prof. Alison ElliotMRC-UVRI and LSHTMMedical Research CouncilOngoing48 Months
890094Population Difference in Vaccine Response: The Role, Reversibility and Mediators of Immunomodulation by Chronic Infections in the Tropics (POPVAC).” – Protocol C: The Impact of BCG ‘Pre-Immunization’ on the Response to Vaccines among Ugandan Adolescents Participating in the Entebbe Mother and Baby Study.28/05/2019Prof. Alison ElliotMRC-UVRI and LSHTMLondon School of Hygiene and Tropical MedicineOngoing36 Months
900095A Randomized, Open-label, Parallel-group, Single Dose Regimen, Phase 2a Study to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 Dose Levels of Artefenomel (OZ439) Given in Combination with Ferroquine (FQ) and FQ Alone, in African Patients with Uncomplicated Plasmodium Falciparum Malaria.02/05/2019Dr. Adoke YekaInfectious Diseases Research CollaborationSanofi-Aventis Recherche and Development; Medicines Malaria Venture (MMV)Closed Out24 Months
910096Trial of Faropenem and Cefadroxil (in Combination with Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients with Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers.16/05/2019Dr. Cissy KityoJoint Clinical Research CentreNational University Hospital, 5 lower Kent Ridge Rd SingaporeClosed out3-4 Months
920098Randomized Trial to Evaluate Mirasol Whole Blood Pathogen Reduction Technology System to Reduce Malaria and Other Transfusion Transmitted Infections (Uganda Mirasol Trial).04/07/2019Dr. Irene LubegaMU-JHUDepartment of Defence, Congressionally Directed Medical Research ProgrammeOngoing42 Months
930099Pharmacokinetics ad Pharmacodynamics of Azithromycin in Severe Malaria Bacterial Co-infection in African Children: TABS PKPD Study25/11/2019Prof. Peter Olupot-OlupotMbale Clinical Research Institute (MCRI)Imperial College London. AIMI Vanden OevenOngoing18 Months
940100Monitored Emergency Use of Unregistered and Experimental Drugs (MEURI): Favipiravir for Exposed Staff to Filovirus (Marbug and Ebola) in Uganda18/06/2019Assoc Prof. Juliet Mwanga AmumpaireMSF Epicenter MbararaMedicines Sans FrontieresOngoingUndetermined
950101Nucleosides and Darunavir/Dolutegravir in Africa (The NADIA Trial): A Randomised Controlled Trial of Darunavir versus Dolutegravir and Tenofovir versus Zidovudine in Second-line Antiretroviral Therapy Regimens for the Public Health Approach in Sub-Saharan Africa11/06/2019Dr. Andrew KambuguInfectious Diseases Institute Infectious Diseases InstituteOngoing36 Months
960102A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined with Local Standard of Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as a Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Children, Adolescents and Adults in Uganda07/04/2019Dr. Henry DdunguUganda Cancer Institute (UCI)Fred Hutchinson Cancer Research CentreOngoing48 Months
970103A Randomized, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagleror versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease11/06/2019Dr. Sylvia KusemererwaMRC/UVRI and LSHTMAstra Zeneca ABTerminated24 Months
980104A Phase I/II Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® with or without AP 10-701 for Intestinal Schistosomiasis in Healthy Ugandan Adults.28/08/2019Dr. Hannah KibuukaMUWRPBaylor College of MedicineOngoing36 Months
990105Monitored Emergency Use for Ebola Virus Disease18/06/2019Dr. Francis KiweewaMUWRPJoint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC) programNot Initiated36 Months
1000106An open-label, single arm study to provide additional information on immunogenicity and safety of Ad26.ZEBOV/MVA-BN-Filo19/06/2019Prof. Pontiano KaleebuMRC/UVRI and LSHTMLondon School of Hygiene and Tropical Medicine LSHTMOngoingUndetermined
1010107Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis (TRUNCATE-TB).16/08/2019Dr. Christine Sekaggya-WiltshireInfectious Diseases InstituteUniversity College London.Closed out36 Months
1020108Remdesivir (GS-5734): Monitored Emergency Use for Ebola Virus Disease. 18/06/2019Dr. Bernard OparMinistry of HealthMedicines Sans Frontieres (MSF)Not Initiated Undetermined
1030109REGN3470-3471-3479: Monitored Emergency Use for Ebola virus Disease. 18/06/2019Dr. Bernard OparMinistry of HealthMedicines Sans Frontieres (MSF)Not InitiatedUndetermined
1040110ZMapp: Monitored Emergency Use for Ebola Virus Disease. Version 1.0 dated 16 December 2018. (ZMAPP)18/06/2019Dr. Bernard OparMinistry of HealthMedicines Sans Frontieres (MSF)Not InitiatedUndetermined
1050111A Phase IV Open-Label Trial to Assess Bone Mineral Density in a Cohort of African Women on Depo-provera and Tenofovir Disoproxil Fumarate Switched to Tenofovir Alafenamide Fumarate based Anti-Retroviral Therapy. (BONE STAR)04/09/2019Dr. Flavia Matovu KiweewaMU-JHU Research CollaborationGilead SciencesOngoing36 Months
1060112Combined HIV Adolescent PrEP and Prevention: On Demand Pre-Exposure Prophylaxis to Provide Protection from HIV in Men using Foreskin Tissue to Estimate Protection (CHAPS II) 19/09/2019Prof. Pontiano KaleebuMRC/UVRI and LSHTM Uganda Research InstitutePerinatal HIV Research Unit, Chris Hani Bagwaranth Academic Hospital, University of Witswater Rand UniversityClosed-out12 Months
1070113Non-Inferiority Fractional-Doses Trial for Yellow Fever Vaccine. (NIFTY)23/09/2019Dr. Maria Louise Namulwana Epicentre Mbarara Research CentreUniversity of Oxford UK. KEMRI-Welcome Trust Research ProgrammeOngoing36 Months
1080114Efficacy and Safety of fexinidazole in patients with Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense: a multicenter, open-label clinical trial 27/12/2019Prof. Enock MatovuMakerere University, College of Veterinary Medicine, Animal Resources and BiosecurityDrugs for Neglected Diseases Initiative (DNDI)Ongoing39 Months
1090115A5300B/12003B/PHOENIx: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIX MDR-TB) 27/09/2019Dr. Henry MugerwaJoint Clinical Research CentreDivision of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), Department of Health and Human Services (DHHS)Ongoing60 Months
1100116A5300B/12003B/PHOENIx: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIX MDR-TB), 21/10/2019Dr. Eric WobudeyaMU-JHUNational Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD)Ongoing60 Months
1110117Population differences in vaccine response: the role, reversibility and mediators of immunomodulation by chronic infections in the tropics (POPVAC). – Protocol B: The effect of intermittent preventive treatment for Malaria with dihydroartemisinin –piperaquine on response to vaccines among rural adolescents. (POPVAC-B)11/09/2019Prof. Alison ElliottMRC-UVRI and LSHTMLondon School of Hygiene and Tropical Medicine (LSHTM)Ongoing48 Months
1120118High Dose Oral Rifampicin to Improve Survival from Adult Tuberculosis Meningitis: A Double-blinded Randomised Controlled Phase III Trial. (HARVEST)23/12/2019Assoc Prof. David MeyaInfectious Diseases Institute Infectious Diseases Institute (IDI)On-going60 Months
1130119Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: A multicenter open label randomized controlled clinical trial (EMPIRICAL)11/03/2020Assoc Prof. Victor MusiimeMUCHSServicia Madrileno de Salud (SERMAS)-Fundacion para la Investigacion BiomedicaOngoing36 Months
1140120Birth Asphyxia in Uganda: Prevalence, Associated Factors and Effect of Intra-Partum Oxygen Administration on Fetal and Early Neonatal Outcomes. (INTRA-O)11/12/2019Ms. Elizabeth Ayebare Department of Nursing, School of Health Sciences, Makerere University.Ayebare ElizabethClosed Out8 Months
1150121Phase 3b, Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy. (DELIVER)06/12/2019Dr. Clemensia NakabittoMU-JHUDivision of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH)Ongoing36 Months
1160122Impact of Increased Praziquantel Frequency On Childhood Fibrosis in Persistent Schistosmiasis Morbidity Hot Spots (FibroScHot)23/01/2020Dr. Edridah TukahebwaVector Control DivisionCambridge University Hospitals NHS Foundation Trust, The Chancellor, Masters and Scholars of the University of CambridgeOngoing32 Months
1170124Safety and efficacy of Dolutegravir and EFV400 for pregnant and breastfeeding women: a randomised non-inferiority clinical trial.08/05/2020Prof. Jackson MukonzoDepartment of Pharmacology and Therapeutics, MAKCHSHawassa University, EthiopiaOngoing
1180125A phase IIb three-arm, two-stage HIV-1 prophylactic vaccine trial with a second randomisation to compare TAF/FTC in comparison to TDF/FTC as pre-exposure prophylaxis (PrEPVacc)26/03/2020Prof. Pontiano KaleebuMRC/UVRIJonathan Weber, Imperial College, Room 2.15, 2 Floor, Faculty Building, South Kesington campus, Exhibition road, LondonOngoing36 Months
1190126A Phase 3, Open-label, Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir administered with Rifampicin to HIV Positive Adults on Second-line ART Regimen with Suppressed HIV-1 Viral Load (DERIVE).22/05/2020Dr. Henry MugerwaJoint Clinical Research CentreUniversity of LiverpoolOngoing18 Months
1200128DPART Study Dihydroatemisinin in the context of Antiretroviral Therapy. (DPART)30/07/2020Dr. Grace Paul KisituBaylor College of Medicine , Children’s FoundationNational Institute of Child Health and Human Development (NICHD)Ongoing
1210129A multicenter, phase III double blind, randomized active controlled study to evaluate the efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants. (VPM)08/07/2020Dr. Victoria NankabirwaMakerere University School of Public HealthSerum Institute of India, Private LimitedOngoing36 Months
1220130Phase 3B, Randomized, Open-label, Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in breastfeeding Mother-infant Pairs. Protocol Version 1.0 dated 24 July 2019. (TRUVADA)03/05/2020Dr. Brenda Gati MirembeMU-JHUDivision of AIDS (DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID)Closed-out24 Months
1230131ROSuvastatin Evaluation as a Tuberculosis Treatment Adjunct (ROSETTA)20/07/2020Dr. Cissy Kityo MutuluuzaJoint Clinical Research CentreNational University HospitalOngoing11 Months
1240132Impact of oral step-down to amoxicillin or co-amoxiclav and of duration of antibiotic therapy on effectiveness, safety and selection of antibiotic resistance in severe childhood community-acquired pneumonia (CAP): a randomized controlled trial. (PediCAP)15/06/2020Assoc Prof. Victor MusiimeDepartment of Pediatrics and Child HealthFondazione PENTA ONLUSOngoing24 Months
1250133Praziquantel for children under age four years: A phase II PK/PD driven dose finding trial (PIP)27/07/2020Dr. Patrice MawaMRC/UVRI AND LSHTMRhode Island Hospital, Center for International Health ResearchOngoing36 Months
1260134Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CABLA) for Prevention of HIV among Female Adolescents-A Sub-study of HPTN084. (CABLA)26/06/2020Dr. Brenda Gati MirembeMU-JHUDivision of AIDS (DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIHOngoing24 Months
1270135Optimal chemopreventive regimens to prevent malaria and improve birth in Uganda, 30/07/2020Prof. Moses KamyaIDRCThe National Institute of Child Health and Human Development (NICHD)Ongoing60 Months
1280136Pharmacokinetics and tolerability of Adjunctive Linezolid for the Treatment of tubERculous meningitis (ALTER): a Phase II trial, open-label, randomized trial (ATLER)11/09/2020Dr. Freddie Mukasa KibengoMRC/UVRI & London School of Hygiene and Tropical MedicineUniversity of California, San FranciscoClosed Out 24 Months
1290137Comparison of Mortality and Frequency of Red Blood Cell Allo-immunization in recipients of Leuko-reduced and Non-Leuko-reduced Blood Transfusion in Uganda.22/09/2020Dr. Clement Dove OkelloUganda Cancer InstituteUganda Cancer Institute (UCI)Closed out 36 Months
1300138Randomized controlled non-inferiority trial of topical chlorhexidine 0.2% versus topical natamycin 5% for fungal keratitis in East Africa30/09/2020Dr. Simon ArungaMbarara University and Referral Eye CenterLondon School of Hygiene and Tropical Medicine (LSHTM)Ongoing36 Months
1310139The safety and imMunogeNicity of a combined Pertussis-cOntaining vaccine (Tdap) for HIV-infected pregnant WomEn and their newboRns-A Randomized Clinical Trial (woMANPOWER)23/09/2020Dr. Eva NakabembeMakerere University College of Health SciencesSt. Georges University of London, Joint Research and Enterprise ServicesOngoing24 Months
1320140An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19 27/12/2021Assoc Prof Juliet Mwanga-AmumpaireEpicentre Mbarara Research CentreDr. Rebecca F. GraisOngoing12 Months
1330141A randomized trial of 6 months intensified anti-tuberculosis and 2 months anti-inflammatory treatment for HIV-infected and HIV-uninfected African and Asian children with tuberculosis meningitis. (SURE STUDY)29/10/2020Dr. Eric WobudeyaMU-JHUUniversity College of LondonOngoing 36 Months
1340142Optimizing DPT-containing vaccine infant immunization schedules in UGANDA. (OPTIMMS)04/02/2021Prof. Alison ElliotMRC/UVRIUniversity of OxfordOngoing48 Months
1350143The Efficacy and Safety of hydroxychloroquine for the treatment of non-severe covid-19 in adults in Uganda. A randomized open label phase II clinical trial (HONEST)09/09/2020Dr. Pauline Byakika-KibwikaMakerere University College of Health SciencesMakerere UniversityTerminated24 Months
1360144Effectives of low-dose Theophylline for the management of Biomass-associated COPD.10/12/2020Dr. Bruce KirengaMakerere University Lung Institute (MLI)National Institute of HealthOngoing24 Months
1370145Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals by addressing Artemether-Lumefantrine and Efavirenz, A randomized Controlled Trial (OPTIMAL)11/03/2020Prof. Pauline Byakika-KibwikaMakerere University College of Health Sciences (MUCHS)Infectious Diseases InstituteOngoing36 Months
1380146Assessment of safety and efficacy of COVID-19 Convalescent Plasma for treatment of COVID-19 in adults in Uganda; A phase III randomized controlled trial. (CCP) 14/09/2020Assoc Prof. Bruce KirengaMakerere University Lung Institute (MLI)Makerere UniversityOngoing5 Months
1390147Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda: A single Arm Open Label Trial. (BRAIN SAFE II)02/12/2020Assoc Prof. Richard IdroMakerere University College of Health Sciences (MUCHS)Global Health Uganda, LimitedOngoing36 Months
1400148Pilot feasibility study for uptake and implementation of a clinical algorithm for warfarin dosing in sub-saharan African patients in the War-PATH Ugandan and South African Clinical study sites.08/01/2021Dr. Catriona WaittIDIUniversity of LiverpoolOngoing18 Months
1410149Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children with Sickle Cell Anemia in Eastern and Southern Africa. (CHEMCHA)19/11/2020Assoc Prof. Richard IdroMUCHSLiverpool School of Tropical Medicine, UKOngoing60 Months
1420150A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease.24/02/2021Dr. Henry DdunguUCIIMARA, Inc C/O Eleanor Lisbon,MD,MPH Vice President, Clinical Development, IMARAEarly termination36 Months
1430151A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease.24/02/2021Dr. Abner TagoolaJinja Regional Referral Hospital, Sickle Cell ClinicIMARA, Inc C/O Eleanor Lisbon,MD,MPH Vice President, Clinical Development, IMARAEarly termination36 Months
1440152A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease24/02/2021Assoc Prof. Victor MusiimeJCRCIMARA, Inc C/O Eleanor Lisbon,MD,MPH Vice President, Clinical Development, IMARAEarly termination36 Months
1450153A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease24/02/2021Dr. Afizi KibuukaIDRCIMARA, Inc C/O Eleanor Lisbon, MD, MPH Vice President, Clinical Development, IMARAEarly termination36 Months
1460154A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease24/02/2021Prof. Grace NdeeziMakerere College of Health Sciences/ Mulago HospitalIMARA, Inc C/O Eleanor Lisbon, MD, MPH Vice President, Clinical Development, IMARAEarly termination36 Months
1470155An Open-Label, Roll-over study with Rilpivirine in Combination with a Background Regimen Containing Other Antiretrovirals (ARVs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in Rilpivirine Pediatric Studies10/02/2021Dr. Francis SsaliJCRCJANSSEN Pharmaceuticals (Pty) LtdOngoing48 Months
1480156Multicenter, Adaptive, Randomized, Blinded Controlled Trial of safety and Efficacy of investigational Therapeutics for hospitalized patients with COVID-1920/01/2021Dr. Joseph LutaakomeMRC/UVRI and LSHTMUniversity of MinnesotaOngoing 36 Months
1490157Effect of Vitamin D supplementation on sickle cell disease hospitalization and related complications among children in Mulago Hospital: A randomized clinical trial22/02/2021Prof. Grace NdeeziDepartment of Pediatrics and Child HealthMakerere Research Innovation Fund (Mak RIF)Ongoing12 Months
1500158Safety and Pharmacokinetics of the combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults 17/02/2021Dr. Andrew MujugiraIDIInternational AIDS Vaccine InitiativeOngoing36 Months
1510159An Open-label, randomized, Single intravenous dosing to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers. (REMTLAR)12/02/2021Prof. Mohammed LamordeIDIInfectious Diseases InstituteOngoing12 Months
1520160Intensified tuberculosis treatment to reduce the mortality of HIV-Infected and HIV-uninfected patients with tuberculosis meningitis: a Phase III Randomized Controlled Trial. (INTENSE-TBM)08/04/2021Dr. Conrad K MuzooraMbarara University of Science and Technology (MUST)Prof. Francois DabisOngoing48 Months
1530161A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-Infected, Virological Suppressed Adults in Sub-Saharan Africa. (CARES)03/03/2021Dr. Cissy KityoJoint Clinical Research Centre Joint Clinical Research CentreOngoing39 Months
1540162The effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination18/08/2021Dr Cissy Kityo MutuluuzaJoint Clinical Research CentreUniversity of MinnesotaOngoing60 Months
1550163A clinical Evaluation of Efficacy, Safety, Immunogenicity and Tolerability of UBV-10N, A Natural Product in Adult Patients Infected with Sar-Cov-2 (Covid-19), In Uganda. (UBV-10N)25/01/2021Dr. Grace Nambatya KyeyuneDirector, Natural Chemotherapeutics Research InstitutePRESIDE (Presidential Scientific Initiative on Epidemics)Ongoing12 Months
1560164Safety and Pharmacokinetics of the combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults. (C100)24/03/2021Dr. Brenda OkechUganda Virus Research Institute/ International AIDS Vaccine Initiative (UVRI/IAVI)International AIDS Vaccine Initiative (IAVI)Ongoing36 Months
1570165Pancreatic Enzymes and Bile Acids: A non-antibiotic approach to Treat Intestinal Dysbiosis in Acutely III Severely Malnourished Children. (PB SAM)15/09/2021Dr. Ezekiel MupereCWRUUniversity of OxfordClosed out36 Months
1580166Paracetamol for Acute Renal Injury in Severe Malaria Trial (PARIST)24/08/2021Prof. Peter Olupot OlupotMbale Clinical Research Institute (MCRI)Mbale Clinical Research InstituteOngoing24 Months
1590167Identification, Validation & Optimization of available drug molecules for clinical treatment of COVID-19. (IVCOM)04/03/2021Prof. Jackson MukonzoDepartment of Pharmacology &TherapeuticsPresidential Scientific Initiative on EpidemicsOngoing12 Months
1600168A randomized Trial to investigate strategies to reduce mortality among HIV-Infected and HIV-exposed children admitted with severe acute malnutrition in Mulago Hospital, Kampala, Uganda. (REDMOTHIV)04/05/2021Assoc Prof. Victor MusiimeMakerere University College of Health SciencesMakerere University Research and Innovations FundOngoing36 Months
1610169A Phase II trial to describe the pharmacokinetics, safety and efficacy of pharmacogenetics-guided dosing of isoniazid in patients with HIV-associated TB (PHINX)13/09/2021Dr. Christine Sekaggya-WiltshireIDIMakerere UniversityOngoing24 Months
1620170Evaluation of pharmacokinetics, safety and feasibility for administration of two doses of intravenous ascorbic acid combined with vitamin B1 for the management of adult patients admitted with sepsis to Kiruddu National Referral Hospital. (REVISTA)08/06/2021Dr. Shevin JacobInfectious Diseases InstituteLiverpool School of Tropical MedicineOngoing12 Weeks
1630171A Phase 1 Trial of ChADOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern African. (HIV-CORE 006)04/06/2021Prof. Pontiano KaleebuMRC/UVRIUniversity of OxfordOngoing21 Months
1640172Gastroenteritis and Rehydration of children with Severe Acute Malnutrition (GASTROSAM)25/11/2021Prof. Peter Olupot-OlupotMCRIImperial College LondonOngoing24 Months
1650173Implementation of a bundle of care to improve anticoagulation control in patients receiving warfarin in Uganda and South Africa. (WARFARIN BUNDLE)19/07/2021Dr. Catriona WaittIDIUniversity of LiverpoolOngoing36 Months
1660174A multi-Centre, randomised, placebo controlled, double-blind, parallel group study to evaluate the safety, tolerability and immunogenicity of two doses of Group B Streptococcus vaccine (GBS-NN/NN2) in women who are pregnant and living with HIV and women who are pregnant and do not have HIV. (MINERVAX)09/07/2021Dr. Musa SekikuboMU-JHUMinervaX A/SOngoing18 Months
1670175Finding Solutions to thrive after birth asphyxia in Africa: An open-label dose-finding clinical trial (Phase Ib study). SANE-Uganda.31/08/2021Dr. Nathan Kenya -MugishaWALIMUResearch Institute of the McGill University Health CentreOngoing18 Months
1680176A5372 Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals. (A5372)16/07/2021Dr. Cissy KityoJCRCNational Institute of Allergy and Infectious DiseasesClosed out 12 Months
1690177A parallel-group, Phase III, multi-stage. Modified double-blind, multi-armed study to assess the efficacy, safety and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older. (VAT0008)11/08/2021Dr. Hannah KibuukaMUWRPSanofi Pasteur, IncOngoing 24 Months
1700178An Open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose In Human Immunogenicity Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen. (EBOVAC BOOST)25/08/2021Prof. Pontiano KaleebuMRC/UVRI/LSHTMLondon School of Hygiene and Tropical Medicine (LSHTM)Ongoing 6 Months
1710179B-ENHANCEMENT of HBV Vaccination in Persons Living With HIV (Bee-HIVe): Evaluation of HEPLISAV-B.08/10/2021Dr. Francis SsaliJCRCNational Institute of Allergy and Infectious Diseases (NIAID)Ongoing 30 Months
1720180A randomized clinical Trial of Early Empiric Anti-Mycobacterium tuberculosis therapy for Sepsis in Sub-Saharan Africa (ATLAS trial)27/09/2021Dr. Conrad K. MuzooraMbarara University of Science and Technology (MUST), Mbarara Regional Referral Hospital National Institute of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases (DMID) Ongoing36 Months
1730181Efficacy and safety of artemether-lumefantrine, pyronaridine- Artesunate, Artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated plasmodium falciparum malaria in children in Uganda09/11/2021Dr. Adoke YekaIDRCUnited States of Agency for International Development (USAID)Ongoing 24 Months
1740182A phase 1 Study to determine the safety and Immunogenicity of candidate Rift Valley Fever virus (RVFV) vaccine ChAdox1 among healthy adult volunteers in Uganda09/11/2021Dr. Irene Andia BiraroMakerere University College of Health SciencesNational Institute of Medical Research-Mbeya Medical Research Centre Ongoing48 Months
1750183A Phase I study to determine the safety and immunogenicity of the candidate Rift Valley Fever Virus (RVFV) vaccine ChAdOx1 RVF among healthy adult volunteers in Uganda (RVF002)29/09/2021Prof. Pontiano KaleebuMRC/UVRI LSHTM Uganda Research Unit, Masaka site.Dr. Stephen ConwayOngoing12 weeks from date of enrollment of the last volunteer (s)
1760184Phase I/II study of the Safety, Acceptability. Tolerability and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents. (IMPAACT 2017)12/11/2021Dr. Violet KorutaroBaylor College of Medicine Children’s Foundation National Institute of Allergy and Infectious Disease Institute (NIAID) and Eunice Kennedy Shriver, National Institute of Child Health and Human Development (NICHD). National Institute of Mental Health (NIMH)Ongoing 84 Months
1770185DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children with HIV Infection Aged 2 to <15 Years Old (D3: PENTA 21)07/10/2021Dr. Cissy KityoJoint Clinical Research CentreFondazione PENTA ONLUSOngoing60 Months (5 years)
1780186A clinical trial to assess the safety and immunogenicity of a modified self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19, in SARS-CoV-2 seronegative and seropositive Ugandan population (COVAC)14/09/2021Prof. Pontiano KaleebuMRC/UVRI LSHTM Uganda Research UnitImperial College LondonOngoing10 Months
1790187Drug Interactions between Dolutegravir (DTG) and escalating-doses of Rifampicin (RIF) Study (DORIS Study)13/12/2021Prof. Mohammed LamordeInfectious Diseases InstituteUniversity of LiverpoolOngoing24 Months
1800189An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyper immune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19. (OTAC)17/11/2021Dr. Joseph LutaakomeMRC/UVRI LSHTM Uganda Research UnitUniversity of Minnesota Ongoing 36 Months
1810190Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccines in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008)16/09/2021Dr. Cissy KityoJoint Clinical Research CentreSouth African Medical Research Council (SAMRC)Ongoing 14 Months
1820191Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccines in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008)20/09/2021Dr. Deo WabwireMU-JHUSouth African Medical Research Council (SAMRC)Ongoing 14 Months
1830192Phase I/II study of the Safety, Acceptability. Tolerability and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents. (IMPAACT 2017)08/11/2021Dr. Maxensia OworMU-JHUDivision of AIDS (DAIDS)Ongoing84 Months
1840193Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008)16/09/2021Dr. Peter James ElyanuBAYLORSouth African Medical Research Council (SAMRC)Ongoing14 Months
1850194Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008)17/09/2021Dr. Annet NanvubyaUVRI/IAVISouth American Medical Research Council (SAMRC)Ongoing14 Months
1860195A phase 3, randomized, active-controlled, double-blind clinical study to evaluate the efficacy and safety of oral Islatravir once-monthly as pre-exposure prophylaxis in cisgender women at high risk for HIV-1 infection. (MK-8591-022/ IMPOWER-022)19/10/2021Dr. Brenda Gati MirembeMU-JHUMerck Sharp & Dohme corp. a subsidiary of Merck & Co. IncOngoing48 Months
1870196Enhancing Immunity to Malaria in Young Children with effective Chemoprevention (MIC-DROP)03/12/2021Prof. Moses KamyaIDRCNational Institute of Child Health and Human DevelopmentOngoing60 Months
1880199A Phase 2, Open-lbel, Single-arm Multicenter Study to evaluate the pharmacokinetics safety tolerabilty and efficacy of swicthing to RPV plus other ARVS in HIV infected children (Age 2 to < years) who are virologically suppressed (PICTURE)10/12/2021Dr. Francis SsaliJCRCJanssen Pharmaceuticals (PTY) LtdOngoing 54 Weeks
1890200A Phase 3 Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis Adolescent Girls and Young Women at Risk of HIV Infection. (PURPOSE-1)01/12/2021Dr. Flavia Matovu KiweewaMU-JHUGilead Sciences. Inc Ongoing72 Months
1900201A randomized open-label 2-arm, 96-week trial evaluate the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-saharan Africa (Breather Plus)13/12/2021Dr. Adeodata R. KekitiinwaBaylorUniversity College of London (UCL), UKOngoing60 Months
1910202Cross-sectional prevalence study of schistosomiasis and soil-transmitted helminthiasis with nested open-label randomised controlled study of evaluating the impact of fatty meal co-administration and double-dosing on albendazole effectiveness against hookworm infection among school-aged children in Mayuge district: Implications for Mayuge NTDs Elimination (MANE) Project24/01/2022Dr. Eun Seok KimLSHTM, World VisionWorld Vision Uganda-Mayuge Neglected Tropical DiseasesClosed out 2 Months
1920203A Multicenter, prospective, randomized, placebo controlled, open label, stepped wedge clinical trial of respiratory support with continuous positive airway pressure or high flow Oxygen therapy in adults with acute hypoxemic respiratory distress in Sub-Saharan Africa. (ARISE)14/12/2021Dr Arthur KwizeraDepartment of Anaesthesia and Critical Care Makerere University College of Health SciencesMakerere University Research UniversityOngoing15 Months
1930204Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum17/01/2022Dr. Victoria NdyanabangiBaylor College of MedicineNational Institute of Allergy and Infectious Diseases (NIAID)Ongoing60 Months
1940205Safety and Efficacy of COVIDEX Therapy in management of covid-19 patients; a randomized controlled clinical trial27/01/2022Prof. Jackson MukonzoMakerere University, College of Health SciencesThe Government of Uganda (GOU) and Jena Herbal LimitedOngoing 12 Months
1950206Determination of Adequate TUberculosis Regimen in Adults and adolescents hospitalised with HIV-associated severe immune suppression. A Phase III controlled randomized clinical trial23/03/2022Dr. Conrad MuzooraEpicentre Mbarara Research Centre/Mbarara University of Science and TechnologyInserm-ANRS French National Institute for Health and Medical Research (Inserm) ANRS Infectious Emergent Diseases- Autonomous Agency of Inserm (ANRS)Ongoing 60 Months
1960208A Randomized, Observer-Blind, Phase 2 Clinical Trial of COVAC-2 in Generally Healthy Adults16/05/2022Prof. Pontiano KaleebuMedical Research Council/ Uganda Virus Research Institute (MRC/UVRI)Vaccine and Infectious Disease Organization (VIDO)Ongoing 20 Months Up to December 2023
1970209Alternative Dosing And Prevention of Transfusion (ADAPT): A prospective study to reduce transfusion requirements for children for children with sickle cell anemia using pharmacokinetics-based hydroxyurea dosing26/05/2022Assoc Prof. Robert O. OpokaMakerere University College of Health Sciences (MUCHS)Cincinnati’s Children's Hospital Medical CenterOngoing 36 Months
1980210Exposure-Response Evaluation of IV Artesunate in Children with Severe Malaria14/09/2022Prof. Pauline Byakika-KibwikaDepartment of MedicineVTEU Contract HHSN2722013000221/IDIOngoing12 Months
1990211Ivermectin-Artemisinin Combination Therapy For Eradication Of Malaria (IVIME)01/08/2022Prof Jackson MukonzoDepartment of Pharmacology and TherapeuticsMaKRIFOngoing 6 Months
2000212A placebo controlled clinical trial investigating the safety and immunogenicity of GBS6 in pregnant women with and without human immunodeficiency virus (HIV) infection and their infants.29/06/2022Dr. Musa SekikuboMUCHSSt George's University of London (SGUL)Ongoing 24 Months
2010214Simplified Treatment for Eclampsia Prevention using Magnesium sulfate: A phase III, randomized, open label, active controlled, multicountry, multicentre, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial)07/02/2023Dr. Nakalembe MiriamMUCHSHRP- The UNDP/UNFPA/UNICEF/WHO/World Bank SpecialOngoing48 months
2020215A Phase III Randomized Double-Blind, Placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant Atezolizumab or placebo and Trastuzimab Emtansine for HERS-Positive breast cancer at high risk of recurrence following preoperative therapy. (ASTEFANIA)21/09/2022Dr. Nixon NiyonzimaUganda Cancer Institute F.Hoffmann-LA Roche AGOngoing14 Years
2030216A Phase III, Randomized, Open-label, Multicenter study evluating the efficacy and safety of adjuvant Giredestrant compared with physician’s choice adjuvant Endocrine monotherapy in patients with Estrogen receptor-positive HERS2-Negative Early Breast Cancer07/11/2022Dr. Jackson OremUganda Cancer InstituteF.Hoffmann-LA Roche AGOngoing10 Years
2040218A phase Ib study to assess the safety and immunogenicity of a recombinant adenovirus-based vaccine against plague in Uganda12/12/2022Dr. Eugene RuzagiraMRC/UVRI/LSHTM Uganda Research UnitUniversity of OxfordOngoing12 Months
2050219A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer. (GO42784)18/11/2022Dr. Fred OkukuSt. Francis Hospital, NsambyaF.Hoffman-La Roche LtdOngoing10 Years
2060220Extension of SEARCH SAPPHIRE Dynamic Choice Prevention Study. (SEARCH SAPPHIRE)29/11/2022Prof. Moses R. KamyaDepartment of Medicine, Makerere UniversityUniversity of California, San FranciscoOngoing 12 Months
2070221Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents with Acute Uncomplicated Plasmodium Falciparum Malaria. (M5717)28/11/2022Dr. Adoke YekaInfectious Diseases Research Collaboration (IDRC)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Frankfurter Str. 250 64293 Darmstadt, GermanyOngoing 25 Months
2080222“Long-Acting Treatment in Adolescents (LATA) - A randomised open label 2-arm 96-week trial in virologically suppressed HIV-1-positive adolescents aged 12-19 years of age in Sub-Saharan Africa.”20/04/2023Dr. Adeodata R. KekitiinwaBaylor College of Medicine Children’s Foundation-UgandaUniversity College of LondonOngoing60 Months
2090223A Phase Ib trial to evaluate the safety and immunogenicity of R21/Matrix-MTM in African children living with HIV (VAC092)25/10/2022Dr. Eugene RuzagiraMRC/UVRI and LSHTM Uganda Research Unit.Jenner Institute, University of OxfordOngoing 24 Months
2100224Efficacy, Safety and Effectiveness of Injectable Cabotegravir/Rilpivirine in Improving HIV-1 Control in Sub-Saharan Africa: A Pragmatic Phase 3b Open- Label Randomized Controlled Trial. (IMPALA)07/11/2022Dr. Eugene RuzagiraMRC/UVRI and LSHTM Uganda Research UnitLondon School of Hygiene and Tropical Medicine through MRC/UVRI & LSHTM Uganda Research UnitOngoing36 Months
2110226A Phase II Multicenter Study of Pomalidomide Monotherapathy in HIV-Positive Individuals with Kaposis Sarcoma (KS) in Sub-Saharan Africa (SSA) 02/02/2023Dr. Jackson OremUganda Cancer Institute (UCI)AIDS Malignancy Consortium (AMC)Ongoing48 Months
2120227“An adaptive, randomized, active-controlled, open-label, sequential cohort,multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of intravenous cipargamin (KAE609) in adult and paediatric participants with severe Plasmodium falciparum malaria (KARISMA – KAE609’s Role in Severe Malaria)”21/08/2023Dr Adoke YekaInfectious Diseases Research CollaborationNovartis Pharma AGOngoing24 Months
2130228REMDESIVIR: Monitored Emergency Use for Filovirus Disease07/11/2022Dr. Olaro CharlesMinistry of Health, UgandaMinistry of Health, UgandaOngoing
2140230Efficacy And Safety of Dihydroartemisinin-Piperaquine (Eurartesim) For Treatment of Uncomplicated P. Falciparum Malaria In Adult Patients With Covid-19 Co-Morbidity: An Open Label Non-Randomised Clinical Trial (EMCOS CLINICAL TRIAL)01/12/2022Dr. Haruna MuwongeMakerere University Lung InstituteMakerere University Lung Institute (MLI)Ongoing 12 Months
2150231Safety, Pharmacokinetics and Preliminary Efficacy of Herbal Products for the Treatment of Acute Respiratory Viral Infections Including SARS-COV2 in Uganda; Phase 2A Open Label Clinical Trial (CONAT)23/01/2023Assoc. Prof. Bruce KirengaMakerere University Lung Institute (MLI)Ministry of Science, Technology and Innovation (MOSTI), Office of the PresidentOngoing 24 Months
2160232Core protocol: Ring Vaccination Trial to Evaluate the Efficacy and Safety of Sudan Ebolavirus Vaccines In Uganda. 25/11/2022Assoc. Prof. Bruce KirengaMakerere University Lung InstituteMinistry of Health Ongoing
2170233A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the prevention of COVID-19 in Participants Aged 18 Years and Older (LVRNA00928/11/2022Dr. Francis KiweewaLira Regional Referral Hospital (SICRA)AIM Vaccine Co. LtdTerminated 24 Months
2180234A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 (ACTIV-2d/A5407)15/03/2023Dr. Afizi KibuukaIDRC Clinic Tororo General HospitalShionogi B.VOngoing24 Months
2190235Cluster randomised controlled trial of a complex intervention package to reduce blindness from severe microbial keratitis in Uganda.14/03/2023Dr. Arunga SimonMbarara University and Referral Hospital Eye CenterLondon School of Hygiene and Tropical MedicineOngoing24 Months
2200236“A Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening TBtreatment).”11/04/2023Prof. Harriet Mayanja-KizzaUganda-CWRU Research CollaborationU.S Centers for Disease Control and Prevention (CDC)Ongoing 60 Months
2210237“Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections”27/06/2023Dr. Joseph LutaakomeMRC/UVRI and LSHTM Uganda Research UnitUniversity of MinnesotaOngoing
2220238Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age, IMPAACT 2036:07/11/2023Dr Victoria NdyanabangiBaylor College of Medicine Children’s Foundation UgandaNational Institute of Allergy and Infectious Diseases Eunice Kennedy Shriver National of Child Health and Human Development National Institute of Mental HealthOngoing42 Months
2230239A multi-part, multi-center PLATform study to assess the efficacy, safety, tolerability and pharmacokinetics of anti-malarial agents administered as monotherapy and/or combination therapy IN patients with Uncomplicated Plasmodium falciparum Malaria.05/10/2023Dr. Adoke YekaInfectious Diseases Research CollaborationNorvatis Pharma AG.Ongoing24 Months
2240240Dihydroartemisinin-piperaquine and azithromycin for the post-discharge management of children with severe anaemia in Malawi, Kenya and Uganda; A, andomized, parallel-group, two-arm, andomized, double-blind superiority trial.(PDMC-II) 01/06/2023Assoc. Prof. Richard IdroMakerere University College of Health SciencesTraining and Research Unit of Excellence (TRUE).Ongoing 36 Months
2250242A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety and Antiviral Activity of the GS9883 /Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Adolescents and Children.26/06/2023Dr Peter James ElyanuBaylor College of Medicine Children’s Foundation-UgandaGilead Sciences Inc.Ongoing96 Weeks
2260243A Phase 2/3 Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK) and efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants (GS-US-216-0218)16/06/2023Dr Flavia Matovu KiweewaMU-JHU Research Collaboration (MU-JHU CARE LTD)Gilead Sciences Inc.Ongoing 30 Months
2270244Gabapentin to Reduce Alcohol and Improve Viral Load Suppression (GRAIL) –Promoting “Treatment as Prevention”03/08/2023Dr. Winnie MuyindikeMbarara University of Science and Technology/Regional Referral Hospital.Jeffrey Samet (Sponsor representative)Ongoing 60 Months
2280245Intramuscular vs Enteral Penicillin Prophylaxis to Prevent Progression of Latent Rheumatic Heart Disease: A non-inferiority randomized trial (GOALIE).22/09/2023Dr. Joselyn RwebemberaUganda Heart InstituteNational Institute of HealthOngoing48 Months
2290246A multiple arm, multiple stage (MAMS), phase 2B/C, open label, randomized controlled platform trial to evaluate experimental arms including an increased dose of rifampicin, an optimized dose of pyrazinamide, moxifloxacin and sutezolid, in adult subjects with newly diagnosed, smear-positive pulmonary tuberculosis”.11/07/2023Assoc. Prof. Bruce KirengaMakerere University Lung InstituteLMU Klinikum Muenchen, Division of Infectious Diseases and Tropical MedicineOngoing36 Months
2300247Evaluating Tumor Evolution And The Clinical Utility Of Circulating Tumor Dna In Patients With Metastatic Breast Cancer Treated With Talazoparib.”08/08/2023Dr. Nixon NiyonzimaUganda Cancer Institute (UCI)Uganda Cancer InstituteOngoing24 Months
2310248A phase 2, partially-blinded, randomized trial assessing the safety and efficacy of TBAJ876 or bedaquiline, in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis09/08/2023Prof Harriet Mayanja-KizzaUganda Case Western Reserve University Research CollaborationTB AllianceOngoing48 Months
2320249A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults Short Title: Sabin 002,28/07/2023Dr. Betty MwesigwaMakerere University Walter Reed ProjectSabin Vaccine Institute.Ongoing48 Months
2330250Earlier prime-BOOST schedule to improve MEasles protection in high burden settings (BoostME)13/10/2023Dr. Ezekiel MupereMakerere University – John Hopkins University Research CollaborationUniversity of OxfordOngoing 36 Months
2340251A5394: Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV.24/11/2023Dr. Francis SsaliJoint Clinical Research,The National Institute of Allergy and Infectious Diseases DAIDS,NIAID, NIH.Ongoing 30 Months
2350252A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety and Antiviral Activity of the GS 9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Adolescents and Children.14/07/2023Dr Flavia Matovu KiweewaMU-JHU Research CollaborationGilead Sciences Inc.Ongoing96 weeks
2360253A randomised, double blinded, placebo-controlled, multi-centre trial of azithromycin prophylaxis for advanced HIV disease. “Reducing Mortality InAdults With Advanced HIV Disease”.02/10/2023Dr. Conrad K. MuzooraMbarara UniversityPopulation Health Research Institute (PHRI)Ongoing 60 Months
2370254“A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Ad26.Mos4.HIV and CH505 TF chTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy Adults.”09/11/2023Dr. Grace MirembeMakerere University Walter Reed ProjectEmily D. Badraslioglu (Acting Representative), The Surgeon General, Department of the ArmyOngoing 24 Months
2380255“, Hydroxyurea – Pragmatic Reduction In Mortality and Economic burden, H-PRIME19/10/2023Prof. Peter Olupot-OlupotMbale Clinical Research InstituteImperial College of LondonOngoing 60 Months
2390256“Platform?Assessing?Regimens?And?Durations?In a?Global?Multisite consortium? for?TB: A seamless Phase 2B/2C platform trial to evaluate multiple regimens and durations of treatment in pulmonary tuberculosis11/04/2024Dr. Cissy KityoJoint Clinical Research CentreUniversity College London, Institute of Clinical Trials and methodologyOngoing 60 Months
2400258“A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo Versus Phesgo After Induction Therapy with Phesgo+Taxane in Patients with Previously Untreated Her2- Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer.”11/12/2023Dr. Nixon NiyonzimaUganda Cancer Institute (UCI),F. Hoffmann-La Roche LTDOngoing 108 Months
2410259“Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis,19/03/2024Assoc Prof. David MeyaInfectious Diseases InstituteAssoc Prof. David MeyaOngoing 12 Months
2420263“A Phase 2/3 Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety and Efficacy of Cobicistat-boosted Atazanavir(ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants05/03/2024Dr Flavia Matovu KiweewaMU-JHU Research Collaboration (MU-JHU CARE LTD)Gilead Sciences, Inc.Ongoing 60 Months
2430265A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults.11/04/2024Dr. Betty MwesigwaMakerere University Walter Reed ProjectSabin Vaccine Institute.Ongoing 60 Months
2440270Characterization of tuberculosis associated lung fibrosis and respiratory impairment, and prevention using doxycycline in a double blind randomized controlled trial,21/06/2024Dr Ahmed DdunguMakerere University Lung InstituteMakerere University Lung InstituteOngoing 24 Months

Abbreviation

MUCHS Makerere University College of Health Sciences
MU-JHU Makerere University – John Hopkins University
MU-UCSF Makerere University – University of California, San Francisco
MRC/UVRI Medical Research Council / Uganda Virus Research Institute
UVRI-IAVI Uganda Virus Research Institute – International AIDS Vaccine Initiative
LSHTM London School of Hygiene and Tropical Medicine
MUST Mbarara University of Science and Technology
MUWRP Makerere University Walter Reed Project
CWRURC Case Western Reserve University Research Collaboration
IDI Infectious Disease Research Collaboration
MOH Ministry of Health Uganda
NIAID National Institute of Allergy and Infectious Diseases
NIH National Institute of Health
MAKRIF Makerere University Research Innovation Fund
UCI Uganda Cancer Institute